Mitochondrial respiratory chain defects in autism and other neurodevelopmental disorders

Journal of Pediatric Biochemistry

Volumn 2, Issue 4, 2012, Pages 213-223

  Chauhan, Abha ^a   Gu, Feng ^a   Chauhan, Ved ^a  

^a NEW YORK STATE INSTITUTE FOR BASIC RESEARCH IN DEVELOPMENTAL DISABILITIES   (United States)

Author keywords

attention deficit hyperactivity disorder; Autism; Down syndrome; electron transport chain; Fragile X syndrome; mitochondria; neurodevelopment; oxidative stress; schizophrenia

Indexed keywords

CYTOCHROME C OXIDASE; LACTIC ACID; MITOCHONDRIAL DNA; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATE SYNTHASE; PYRUVIC ACID; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE; SUCCINATE DEHYDROGENASE; UBIQUINOL CYTOCHROME C REDUCTASE;

ATTENTION DEFICIT DISORDER; AUTISM; CHROMOSOME DUPLICATION; DEGENERATIVE DISEASE; DEVELOPMENTAL DISORDER; DISEASE ASSOCIATION; DISEASE MODEL; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DOWN SYNDROME; ENERGY METABOLISM; ENZYME ACTIVITY; FRAGILE X ASSOCIATED TREMOR ATAXIA SYNDROME; FRAGILE X SYNDROME; GENE; GENE MUTATION; GENETIC REGULATION; HAPPY PUPPET SYNDROME; HUMAN; LACTATE BLOOD LEVEL; MITOCHONDRIAL ENERGY TRANSFER; MOLECULAR DYNAMICS; NADH UBIQUINONE OXIDOREDUCTASE 1 ALPHA SUBCOMPLEX 5 GENE; NEURODEVELOPMENTAL DISORDER; NONHUMAN; OXIDATIVE PHOSPHORYLATION; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RESPIRATORY CHAIN; RETT SYNDROME; REVIEW; SCHIZOPHRENIA;

EID: 84877871019     PISSN: 18795390     EISSN: 18795404     Source Type: Journal    
DOI: 10.3233/JPB-120063     Document Type: Review

References (119)

1. Bertram R, Gram PM, Luciani DS, Sherman A. A simplified model for mitochondrial ATP production. J Theor Biol 2006; 243: 575-586.
2. Szewczyk A, Wojtczak L. Mitochondria as a pharmacological target. Pharmacol Rev 2002; 54: 101-127.
3. Boekema EJ, Braun HP. Supramolecular structure of the mitochondrial oxidative phosphorylation system. J Biol Chem 2007; 282: 1-4.
4. Dudkina NV, Eubel H, Keegstra W, Boekema EJ, Braun HP. Structure of a mitochondrial supercomplex formed by respiratory-chain complexes I and III. Proc Natl Acad Sci U S A 2005; 102: 3225-3229.
5. Cotter D, Guda P, Fahy E, Subramaniam S. MitoProteome: mitochondrial protein sequence database and annotation system. Nucleic Acids Res 2004; 32: D463-D467.
6. Shadel GS. Expression and maintenance of mitochondrial DNA: new insights into human disease pathology. Am J Pathol 2008; 172: 1445-1456.
7. Shadel GS, Pan Y. Multi-faceted regulation of mitochondria by TOR. Cell Cycle 2009; 8: 2143.
8. Mattson MP, Liu D. Energetics and oxidative stress in synaptic plasticity and neurodegenerative disorders. Neuromolecular Med 2002; 2: 215-231.
9. Polster BM, Fiskum G. Mitochondrial mechanisms of neural cell apoptosis. J Neurochem 2004; 90: 1281-1289.
10. Cadenas E,Davies KJ. Mitochondrial free radical generation, oxidative stress, and aging. Free Radic Biol Med 2000; 29: 222-230.
11. Lenaz G. The mitochondrial production of reactive oxygen species: mechanisms and implications in human pathology. IUBMB Life 2001; 52: 159-164.
12. Hansen JM, Go YM, Jones DP. Nuclear and mitochondrial compartmentation of oxidative stress and redox signaling. Annu Rev Pharmacol Toxicol 2006; 46: 215-234.
13. Jones DP. Disruption of mitochondrial redox circuitry in oxidative stress. Chem Biol Interact 2006; 163: 38-53.
14. Kelley MR, Parsons SH. Redox regulation of the DNA repair function of thehumanAPendonucleaseApe1/ref-1.Antioxid Redox Signal 2001; 3: 671-683.
15. McCord JM. The evolution of free radicals and oxidative stress. Am J Med 2000; 108: 652-659.
16. Muller FL, Liu Y, Van Remmen H. Complex III releases superoxide to both sides of the inner mitochondrial membrane. J Biol Chem 2004; 279: 49064-49073.
17. Barja G. Mitochondrial oxygen radical generation and leak: sites of production in states 4 and 3, organ specificity, and relation to aging and longevity. J Bioenerg Biomembr 1999; 31: 347-366.
18. Sugioka K, Nakano M, Totsune-Nakano H, Minakami H, Tero-Kubota S, Ikegami Y. Mechanism of O2- generation in reduction and oxidation cycle of ubiquinones in a model of mitochondrial electron transport systems. Biochim Biophys Acta 1988; 936: 377-385.
19. Lord C, Cook EH, Leventhal BL, Amaral DG. Autism spectrum disorders. Neuron 2000; 28: 355-363.
20. Wingate,M,Mulvihill B, KirbyRS et al. Prevalence of autism spectrum disorders - Autism and Developmental Disabilities Monitoring Network, 14 sites, United States, 2008. MMWR Surveill Summ 2012; 61: 1-19.
21. Kim YS, Leventhal BL, Koh YJ et al. Prevalence of autism spectrum disorders in a total population sample. Am J Psychiatry 2011; 168: 904-912.
22. ChauhanA,Gu F, EssaMMet al. Brain region-specific deficit in mitochondrial electron transport chain complexes in children with autism. J Neurochem 2011; 117: 209-220.
23. Chugani DC, Sundram BS, Behen M, Lee ML, Moore GJ. Evidence of altered energy metabolism in autistic children. Prog Neuropsychopharmacol Biol Psychiatry 1999; 23: 635- 641.
24. Minshew NJ, Goldstein G, Dombrowski SM, Panchalingam K, Pettegrew JW. A preliminary 31P MRS study of autism: evidence for undersynthesis and increased degradation of brain membranes. Biol Psychiatry 1993; 33: 762-773.
25. Lombard J. Autism: A mitochondrial disorder? Med Hypotheses 1998; 50: 497-500.
26. Guevara-Campos J, Gonzalez-Guevara L, Briones P et al. Autism associated to a deficiency of complexes III and IV of the mitochondrial respiratory chain. Invest Clin 2010; 51: 423-431.
27. Filiano JJ, Goldenthal MJ, Rhodes CH, Marin-Garcia J. Mitochondrial dysfunction in patients with hypotonia, epilepsy, autism, and developmental delay: HEADD syndrome. J Child Neurol 2002; 17: 435-439.
28. Weissman JR, Kelley RI, Bauman ML et al. Mitochondrial disease in autism spectrum disorder patients: A cohort analysis. PLoS One 2008; 3: e3815.
29. Oliveira G, Diogo L, Grazina M et al. Mitochondrial dysfunction in autism spectrum disorders: A population-based study. Dev Med Child Neurol 2005; 47: 185-189.
30. Correia C, Coutinho AM, Diogo L et al. Brief report: High frequency of biochemical markers for mitochondrial dysfunction in autism: No association with the mitochondrial aspartate/glutamate carrier SLC25A12 gene. J Autism Dev Disord 2006; 36: 1137-1140.
31. Filipek PA, Juranek J, Nguyen MT, Cummings C, Gargus JJ. Relative carnitine deficiency in autism. J Autism Dev Disord 2004; 34: 615-623.
32. RossignolDA, FryeRE. Mitochondrial dysfunction in autism spectrum disorders: A systematic review and meta-analysis. Mol Psychiatry 2012; 17: 290-314.
33. Palmieri L, PersicoAM. Mitochondrial dysfunction in autism spectrum disorders: cause or effect? Biochim Biophys Acta 2010; 1797: 1130-1137.
34. Rossignol DA, Bradstreet JJ. Evidence of mitochondrial dysfunction in autism and implications for treatment. Am J Biochem Biotech 2008; 4: 208-217.
35. Gargus JJ, Imtiaz F.Mitochondrial energy-deficient endophenotype in autism. Am J Biochem Biotech 2008; 4: 198-207.
36. Haas RH. Autism and mitochondrial disease. Dev Disabil Res Rev 2010; 16: 144-153.
37. Tsao CY, Mendell Jr. Autistic disorder in 2 children with mitochondrial disorders. J Child Neurol 2007; 22: 1121- 1123.
38. Ozonoff S,Williams BJ, Landa R. Parental report of the early development of children with regressive autism: The delaysplus- regression phenotype. Autism 2005; 9: 461-486.
39. GoldbergWA,Osann K, Filipek PAet al. Language and other regression: Assessment and timing. J Autism Dev Disord 2003; 33: 607-616.
40. Hansen RL, Ozonoff S, Krakowiak P et al. Regression in autism: prevalence and associated factors in the CHARGE Study. Ambul Pediatr 2008; 8: 25-31.
41. Stefanatos GA. Regression in autistic spectrum disorders. Neuropsychol Rev 2008; 18: 305-319.
42. Poling JS, Frye RE, Shoffner J, Zimmerman AW. Developmental regression and mitochondrial dysfunction in a child with autism. J Child Neurol 2006; 21: 170-172.
43. Shoffner J, Hyams L, Langley GN et al. Fever plus mitochondrial disease could be risk factors for autistic regression. J Child Neurol 2010; 25: 429-434.
44. Chauhan A, Essa, MM, Muthaitah B, Brown WT, Chauhan V. Mitochondrial abnormalities in lymphoblasts from autism. J Neurochem 2009; 109 (Suppl 1): 273.
45. James SJ, Rose S, Melnyk S, et al. Cellular andmitochondrial glutathione redox imbalance in lymphoblastoid cells derived from children with autism. FASEB J. 2009; 23: 2374-2383.
46. Holtzman D. Autistic spectrum disorders and mitochondrial encephalopathies. Acta Paediatr 2008; 97: 859-860.
47. GiuliviC, ZhangYF,Omanska-KlusekAet al.Mitochondrial dysfunction in autism. JAMA 2010; 304: 2389-2396.
48. Chauhan A, Chauhan V. Oxidative stress in autism. Pathophysiology 2006; 13: 171-181.
49. McGinnisWR.Oxidative stress in autism.Altern TherHealth Med 2004; 10: 22-36.
50. Chauhan A, Chauhan V. Brain oxidative stress andmitochondrial abnormalities in autism: In: Consensus paper: pathological role of the cerebellum in autism (Fatemi SH et al.). Cerebellum 2012; 11: 777-807.
51. ChauhanA,ChauhanV,BrownWT,Cohen I.Oxidative stress in autism: Increased lipid peroxidation and reduced serum levels of ceruloplasmin and transferrin - the antioxidant proteins. Life Sci 2004; 75: 2539-2549.
52. James SJ, Cutler P, Melnyk S et al. Metabolic biomarkers of increased oxidative stress and impaired methylation capacity in children with autism. Am J Clin Nutr 2004; 80: 1611- 1617.
53. Zoroglu SS, Armutcu F, Ozen S et al. Increased oxidative stress and altered activities of erythrocyte free radical scavenging enzymes in autism. Eur Arch Psychiatry Clin Neurosci 2004; 254: 143-147.
54. Sogut S, Zoroglu SS, Ozyurt H et al. Changes in nitric oxide levels and antioxidant enzyme activities may have a role in the pathophysiological mechanisms involved in autism. Clin Chim Acta 2003; 331: 111-117.
55. Ming X, Stein TP, Brimacombe M, Johnson WG, Lambert GH, Wagner GC. Increased excretion of a lipid peroxidation biomarker in autism. Prostaglandins Leukot Essent Fatty Acids 2005; 73: 379-384.
56. Lopez-Hurtado E, Prieto JJ. A microscopic study of language-related cortex in autism. Am J Biochem Biotech 2008; 4: 130-145.
57. Evans TA, Perry G, Smith MA et al. Evidence for oxidative damage in the autistic brain. In: Chauhan A., Chauhan V. and Brown W.T. (eds), Autism: Oxidative stress, inflammation and immune abnormalities, CRC Press, Taylor and Francis groups, Florida, 2009, pp. 35-46.
58. Muthaiyah B, Essa MM, Chauhan V, Brown WT, Wegiel J, Chauhan A. Increased lipid peroxidation in cerebellum and temporal cortex of brain in autism. J Neurochem 2009; 108 (Suppl. 1): 73.
59. Sajdel-Sulkowska EM, Xu M, Koibuchi N. Increase in cerebellar neurotrophin-3 and oxidative stress markers in autism. Cerebellum 2009; 8: 366-372.
60. Schroer RJ, Phelan MC, Michaelis RC et al. Autism and maternally derived aberrations of chromosome 15q. Am J Med Genet 1998; 76: 327-336.
61. Gillberg C. Chromosomal disorders and autism. J Autism Dev Disord 1998; 28: 415-425.
62. Cleary N. Sudden death in chromosome 15q11-q13 duplication syndrome. http://www. idic15.org/PhysicianAdvisory Feb2009.pdf.
63. Filipek PA, Juranek J, Smith Met al. Mitochondrial dysfunction in autistic patients with 15q inverted duplication. Ann Neurol 2003; 53: 801-804.
64. Ezugha H, Goldenthal M, Valencia I, Anderson CE, Legido A, Marks H. 5q14.3 deletion manifesting as mitochondrial disease and autism: Case report. J Child Neurol 2010; 25: 1232-1235.
65. Pons R, Andreu AL, Checcarelli N et al. Mitochondrial DNA abnormalities and autistic spectrum disorders. J Pediatr 2004; 144: 81-85.
66. Graf WD, Marin-Garcia J, Gao HG et al. Autism associated with the mitochondrial DNA G8363A transfer RNA(Lys) mutation. J Child Neurol 2000; 15: 357-361.
67. Marui T, Funatogawa I, Koishi S et al. The NADHubiquinone oxidoreductase 1 alpha subcomplex 5 (NDUFA5) gene variants are associated with autism. Acta Psychiatr Scand 2011; 123: 118-124.
68. Taurines R, Thome J, Duvigneau JC et al. Expression analyses of the mitochondrial complex I 75-kDa subunit in early onset schizophrenia and autism spectrum disorder: increased levels as a potential biomarker for early onset schizophrenia. Eur Child Adolesc Psychiatry 2010; 19: 441-448.
69. AmirRE,VandV, I,Wan M, Tran CQ, Francke U, ZoghbiHY. Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. Nat Genet 1999; 23: 185-188.
70. Coker SB, Melnyk AR. Rett syndrome and mitochondrial enzyme deficiencies. J Child Neurol 1991; 6: 164-166.
71. Heilstedt HA, Shahbazian MD, Lee B. Infantile hypotonia as a presentation of Rett syndrome. Am J Med Genet 2002; 111: 238-242.
72. Ruch A, Kurczynski TW, Velasco ME. Mitochondrial alterations in Rett syndrome. Pediatr Neurol 1989; 5: 320-323.
73. Eeg-Olofsson O, al Zuhair AG, Teebi AS et al. Rett syndrome: a mitochondrial disease? J Child Neurol 1990; 5: 210-214.
74. Dotti MT, Manneschi L, Malandrini A, De Stefano N, Caznerale F, Federico A. Mitochondrial dysfunction in Rett syndrome. An ultrastructural and biochemical study. Brain Dev 1993; 15: 103-106.
75. Stradomska TJ, Tylki-Szymanska A, Bentkowski Z. Very long-chain fatty acids in Rett syndrome. Eur J Pediatr 1999; 158: 226-229.
76. Su H, Fan W, Coskun PE et al. Mitochondrial dysfunction in CA1 hippocampal neurons of the UBE3A deficient mouse model for Angelman syndrome. Neurosci Lett 2011; 487: 129-133.
77. Kriaucionis S, Paterson A, Curtis J, Guy J, Macleod N, Bird A. Gene expression analysis exposes mitochondrial abnormalities in a mouse model of Rett syndrome. Mol Cell Biol 2006; 26: 5033-5042.
78. Faraone SV, Sergeant J, Gillberg C, Biederman J. The worldwide prevalence of ADHD: is it an American condition? World Psychiatry 2003; 2: 104-113.
79. Bradstreet JJ, Smith S, Baral M, Rossignol DA. Biomarkerguided interventions of clinically relevant conditions associated with autism spectrum disorders and attention deficit hyperactivity disorder. Altern Med Rev 2010; 15: 15-32.
80. PapaM, Sellitti S, SadileAG. Remodeling of neural networks in the anterior forebrain of an animal model of hyperactivity and attention deficits as monitored by molecular imaging probes. Neurosci Biobehav Rev 2000; 24: 149-156.
81. Fagundes AO, Rezin GT, Zanette F et al. Chronic administration of methylphenidate activates mitochondrial respiratory chain in brain of young rats. Int J Dev Neurosci 2007; 25: 47-51.
82. Fagundes AO, Scaini G, Santos PM et al. Inhibition of mitochondrial respiratory chain in the brain of adult rats after acute and chronic administration of methylphenidate. Neurochem Res 2010; 35: 405-411.
83. Bubber P, Tang J, Haroutunian V et al. Mitochondrial enzymes in schizophrenia. J Mol Neurosci 2004; 24: 315-321.
84. RezinGT,Amboni G, Zugno AI,Quevedo J, StreckEL. Mitochondrial dysfunction and psychiatric disorders. Neurochem Res 2009; 34: 1021-1029.
85. Scaglia F. The role of mitochondrial dysfunction in psychiatric disease. Dev Disabil Res Rev 2010; 16: 136-143.
86. Maurer I, Zierz S, Moller H. Evidence for a mitochondrial oxidative phosphorylation defect in brains from patients with schizophrenia. Schizophr Res 2001; 48: 125-136.
87. Fujimoto T, Nakano T, Takano T, Hokazono Y, Asakura T, Tsuji T. Study of chronic schizophrenics using 31P magnetic resonance chemical shift imaging. Acta Psychiatr Scand 1992; 86: 455-462.
88. Kegeles LS,Humaran TJ, Mann JJ. In vivo neurochemistry of the brain in schizophrenia as revealed bymagnetic resonance spectroscopy. Biol Psychiatry 1998; 44: 382-398.
89. Volz HR, Riehemann S, Maurer I et al. Reduced phosphodiesters and high-energy phosphates in the frontal lobe of schizophrenic patients: A (31)P chemical shift spectroscopic- imaging study. Biol Psychiatry 2000; 47: 954-961.
90. Ben Shachar D. Mitochondrial dysfunction in schizophrenia: A possible linkage to dopamine. J Neurochem 2002; 83: 1241-1251.
91. Uranova NA, Aganova EA. Ultrastructure of the synapses of the anterior limbic cortex in schizophrenia. Zh Nevropatol Psikhiatr Im S S Korsakova 1989; 89: 56-59 (in Russian).
92. Kung L, Roberts RC. Mitochondrial pathology in human schizophrenic striatum: A postmortem ultrastructural study. Synapse 1999; 31: 67-75.
93. Cavelier L, Jazin EE, Eriksson I et al. Decreased cytochromec oxidase activity and lack of age-related accumulation of mitochondrial DNAdeletions in the brains of schizophrenics. Genomics 1995; 29: 217-224.
94. Andreazza AC, Shao L, Wang JF, Young LT. Mitochondrial complex I activity and oxidative damage to mitochondrial proteins in the prefrontal cortex of patients with bipolar disorder. Arch Gen Psychiatry 2010; 67: 360-368.
95. Prince JA, Blennow K, Gottfries CG, Karlsson I, Oreland L. Mitochondrial function is differentially altered in the basal ganglia of chronic schizophrenics. Neuropsychopharmacology 1999; 21: 372-379.
96. Whatley SA, Curti D, Marchbanks RM. Mitochondrial involvement in schizophrenia and other functional psychoses. Neurochem Res 1996; 21: 995-1004.
97. Buchsbaum MS, Haier RJ, Potkin SG, et al. Frontostriatal disorder of cerebral metabolism in never-medicated schizophrenics. Arch Gen Psychiatry. 1992; 49: 935-942
98. Holcomb HH, Cascella NG, Thaker GK, Medoff DR, Dannals RF, Tamminga CA. Functional sites of neuroleptic drug action in the human brain: PET/FDG studies with and without haloperidol. Am J Psychiatry. 1996; 153:41-49.
99. Reddy RD, Yao JK. Free radical pathology in schizophrenia: A review. Prostaglandins Leukot Essent Fatty Acids 1996; 55: 33-43.
100. Yao JK, Reddy RD, van Kammen DP. Oxidative damage and schizophrenia: an overview of the evidence and its therapeutic implications. CNS Drugs 2001; 15: 287-310.
101. Dietrich-Muszalska A, Kontek B. Lipid peroxidation in patients with schizophrenia. Psychiatry Clin Neurosci 2010; 64: 469-475.
102. Dadheech G, Mishra S, Gautam S, Sharma P. Evaluation of antioxidant deficit in schizophrenia. Indian J Psychiatry 2008; 50: 16-20.
103. Skinner AO, Mahadik SP, Garver DL. Thiobarbituric acid reactive substances in the cerebrospinal fluid in schizophrenia. Schizophr Res 2005; 76: 83-87.
104. Akyol O, Herken H, Uz E et al. The indices of endogenous oxidative and antioxidative processes in plasma from schizophrenic patients. The possible role of oxidant/antioxidant imbalance. Prog Neuropsychopharmacol Biol Psychiatry 2002; 26: 995-1005.
105. Kuloglu M, Ustundag B, Atmaca M, Canatan H, Tezcan AE, Cinkilinc N. Lipid peroxidation and antioxidant enzyme levels in patients with schizophrenia and bipolar disorder. Cell Biochem Funct 2002; 20: 171-175.
106. Iwamoto K, Bundo M, Kato T. Altered expression of mitochondria-related genes in postmortem brains of patients with bipolar disorder or schizophrenia, as revealed by largescale DNA microarray analysis. Hum Mol Genet 2005; 14: 241-253.
107. Ji B, La Y, Gao L et al. A comparative proteomics analysis of rat mitochondria from the cerebral cortex and hippocampus in response to antipsychotic medications. J Proteome Res 2009; 8: 3633-3641.
108. Lowenthal R, Paula CS, Schwartzman JS, Brunoni D, Mercadante MT. Prevalence of pervasive developmental disorder in Down's syndrome. J Autism Dev Disord 2007; 37: 1394-1395.
109. Kim SH, Vlkolinsky R, Cairns N, Fountoulakis M, Lubec G. The reduction of NADH ubiquinone oxidoreductase 24- and 75-kDa subunits in brains of patients with Down syndrome and Alzheimer's disease. Life Sci 2001; 68: 2741-2750.
110. Kim SH, Vlkolinsky R, Cairns N, Lubec G. Decreased levels of complex III core protein 1 and complex V beta chain in brains from patients with Alzheimer's disease and Down syndrome. Cell Mol Life Sci 2000; 57: 1810-1816.
111. Valenti D,Manente GA, Moro L, Marra E, Vacca RA. Deficit of complex I activity in human skin fibroblasts with chromosome 21 trisomy and overproduction of reactive oxygen species by mitochondria: involvement of the cAMP/PKA signalling pathway. Biochem J 2011; 435: 679-688.
112. Krapfenbauer K, Yoo BC, Cairns N, Lubec G. Differential display reveals deteriorated mRNA levels of NADH3 (complex I) in cerebellum of patients with Down syndrome. J Neural Transm Suppl 1999; 57: 211-220.
113. Bambrick LL, Fiskum G. Mitochondrial dysfunction in mouse trisomy 16 brain. Brain Res 2008; 1188: 9-16.
114. Verkerk AJ, Pieretti M, Sutcliffe JS et al. Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome. Cell 1991; 65: 905-914.
115. Hernandez RN, Feinberg RL, Vaurio R, Passanante NM, Thompson RE, Kaufmann WE. Autism spectrum disorder in fragile X syndrome: A longitudinal evaluation. Am J Med Genet A 2009; 149A: 1125-1137.
116. Bechara EG, Didiot MC, Melko M et al. A novel function for fragile X mental retardation protein in translational activation. PLoS Biol 2009; 7: e16.
117. Wallace DC. A mitochondrial paradigm of metabolic and degenerative diseases, aging, and cancer: A dawn for evolutionary medicine. Annu Rev Genet 2005; 39: 359-407.
118. Ross-Inta C, Omanska-Klusek A, Wong S et al. Evidence of mitochondrial dysfunction in fragile X-associated tremor/ ataxia syndrome. Biochem J 2010; 429: 545-552.
119. Napoli E, Ross-Inta C, Wong S et al. Altered zinc transport disrupts mitochondrial protein processing/import in fragile X-associated tremor/ataxia syndrome. HumMol Genet 2011; 20: 3079-3092.